

PPAPDC1B antibody - middle region

Rabbit Polyclonal Antibody Catalog # AI13123

Product Information

Application WB
Primary Accession Q8NEB5

Other Accession NM 001102559, NP 001096029

Reactivity Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Dog, Guinea Pig, Horse, Bovine

Predicted Human, Mouse, Rat, Dog, Guinea Pig, Bovine

Host Rabbit
Clonality Polyclonal
Calculated MW 29484

Additional Information

Gene ID 84513

Alias Symbol DPPL1, HTPAP

Other Names Phosphatidate phosphatase PPAPDC1B, 3.1.3.4, Phosphatidic acid

phosphatase type 2 domain-containing protein 1B, PPAPDC1B, DPPL1, HTPAP

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

Reconstitution & Storage Add 50 ul of distilled water. Final anti-PPAPDC1B antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

20°C. Avoid repeat freeze-thaw cycles.

Precautions PPAPDC1B antibody - middle region is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information

Name PLPP5 (HGNC:25026)

Function Magnesium-independent phospholipid phosphatase with broad substrate

specificity (PubMed:<u>17590538</u>). Preferentially catalyzes the conversion of diacylglycerol pyrophosphate into phosphatidate but can also act on phosphatidate and lysophosphatidate (PubMed:<u>17590538</u>). Phospholipid phosphatases are involved in both the synthesis of lipids and the generation

or degradation of lipid-signaling molecules (PubMed: 17590538).


Cellular Location Cell membrane; Multi-pass membrane protein

{ECO:0000250 | UniProtKB:Q3UMZ3}

References

Takeuchi M.,et al.Gene 399:174-180(2007). Nusbaum C.,et al.Nature 439:331-335(2006). Li Y.,et al.Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases. Wu X.,et al.Oncogene 25:1832-1840(2006).

Images



WB Suggested Anti-PPAPDC1B Antibody Titration: 0.2-1 μ g/ml Positive Control: Human brain

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.